Optimal human pathogenic T_H2 cell effector function requires local epithelial cytokine signaling

Area of Science:

• Immunology
• Allergy Research
• T-cell Biology

Background:

• Interleukin-33 (IL-33) is increasingly recognized as a key mediator in the development of allergic diseases.
• The IL-33 receptor, suppressor of tumorigenicity 2 (ST2), is expressed on pathogenic T helper 2 (T_H2) cells, but its precise role in T-cell effector functions remains unclear.

Purpose of the Study:

• To investigate the role of IL-33 in modulating circulating allergen-specific T-cell responses.
• To determine if selective ST2 expression on allergen-specific CD4⁺ T cells influences their susceptibility to IL-33.
• To identify ST2 as a potential marker for T_H2A cell activation and function in allergic individuals.

Main Methods:

• Peripheral blood mononuclear cells (PBMCs) were collected from individuals with and without allergies.
• Allergen-specific CD4⁺ T cells were profiled using flow cytometry, including CD154 upregulation assays and MHC class II tetramer staining.
• Cytokine production (IL-4, IL-5) by allergen-specific T cells was assessed upon IL-33 exposure.
• ST2 expression was quantified using a flow-based assay.

Main Results:

• ST2 expression was exclusively found on peripheral allergen-specific CD4⁺ T cells from allergic subjects, specifically on T_H2A cells.
• ST2 served as a reliable marker for T_H2A cell activation when compared to functional assays.
• IL-33 exposure significantly enhanced IL-4 and IL-5 secretion from allergen-reactive T_H2A cells.
• Allergen-induced ST2 expression effectively tracked allergen-reactive T_H2A cells.

Conclusions:

• ST2 expression on circulating CD4⁺ T cells signifies a transient phenotype linked to T_H2A cell activation.
• This ST2 expression allows activated T_H2A cells to respond to local tissue cytokines like IL-33.
• IL-33 selectively amplifies pathogenic T_H2 cell functions, suggesting a regulatory checkpoint in adaptive allergic immunity.